The United States Food and Drug Administration (FDA) is making a significant move to permanently authorize the rare pediatric disease…
Read More
Everest Medicines Acquires Hasten Biopharmaceuticals for $250 Million to Bolster Asia Pacific Chronic Disease Portfolio and Commercial Reach
Everest Medicines, a leading biopharmaceutical company focused on developing and commercializing innovative medicines for chronic diseases, has announced a significant…
Read More
Halozyme and Vertex sign deal for Hypercon technology
Halozyme Therapeutics, a pioneer in drug delivery technologies, has announced a significant global exclusive partnership and license agreement with Vertex…
Read More
US Imposes 100% Tariff on Branded Pharmaceuticals, Sparking Industry Concerns and Geopolitical Debate
The pharmaceutical industry is bracing for significant disruption following the US administration’s recent decision to implement a 100% tariff on…
Read More
Sidewinder Therapeutics Secures $137 Million in Series B Financing to Advance Bispecific Antibody-Drug Conjugate Pipeline
Sidewinder Therapeutics has announced the successful closure of a substantial $137 million Series B financing round, a significant development signaling…
Read More
RoosterBio and MineBio Forge Exclusive Partnership to Accelerate MSC and Exosome Therapies in China
RoosterBio, a prominent innovator in the field of mesenchymal stem cell (MSC) and exosome bioprocessing, has announced an exclusive distributor…
Read More
The Hyper-Connected Hospital: Bridging the Gap Between Digital Ambition and Network Readiness
The healthcare landscape is undergoing a profound metamorphosis, transforming hospitals into hyper-connected environments where artificial intelligence applications, remote patient monitoring,…
Read More
US Import Tariffs Fail to Deter Biopharma Giants as European Contract Manufacturing Surges for FDA-Approved Drugs
The biopharmaceutical industry is demonstrating a significant and counterintuitive trend in 2025, with companies increasingly channeling investments into European-based contract…
Read More
Gilead Acquires Antibody-Drug Conjugate Pioneer Tubulis for Up to $5 Billion, Bolstering Oncology Pipeline
Sixteen months after forging a strategic collaboration, Gilead Sciences has announced its definitive agreement to acquire German biotechnology firm Tubulis,…
Read More
Apnimed Secures Up to $150 Million in Credit Facility to Fuel Potential US Launch of Obstructive Sleep Apnea Therapy AD109
Boston, MA – – Apnimed, a clinical-stage biopharmaceutical company focused on developing novel therapies for sleep-related breathing disorders, has announced…
Read MoreYOU MAY HAVE MISSED
